Volume | 222 |
|
|||||
News | - | ||||||
Day High | 6.06 | Low High |
|||||
Day Low | 6.06 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aprea Therapeutics Inc | APRE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
6.06 | 6.06 | 6.06 | 6.07 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
15 | 222 | - | 2.78 - 8.8465 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
09:32:07 | 2 | $ 5.98 | USD |
Aprea Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
22.68M | 3.74M | - | 0 | -112.66M | -30.15 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aprea Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APRE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.67 | 6.67 | 5.88 | 6.21 | 18,902 | -0.61 | -9.15% |
1 Month | 7.34 | 8.8465 | 5.05 | 6.73 | 76,439 | -1.28 | -17.44% |
3 Months | 5.28 | 8.8465 | 4.8201 | 6.55 | 37,029 | 0.78 | 14.77% |
6 Months | 4.00 | 8.8465 | 3.35 | 5.97 | 23,534 | 2.06 | 51.50% |
1 Year | 4.68 | 8.8465 | 2.78 | 4.65 | 26,548 | 1.38 | 29.49% |
3 Years | 101.00 | 156.00 | 2.78 | 81.18 | 656,527 | -94.94 | -94.00% |
5 Years | 309.20 | 1,062.20 | 2.78 | 118.74 | 571,589 | -303.14 | -98.04% |
Aprea Therapeutics Description
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). |